Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device [Yahoo! Finance]
Daxor Corporation - Closed End Fund (DXR)
NASDAQ:AMEX Investor Relations:
daxor.com/investors
Company Research
Source: Yahoo! Finance
This decision comes after considerable progress in addressing key regulatory considerations and aims to expedite the approval process, potentially bringing this innovative technology to patients sooner. "We're excited about the positive momentum in our discussions with the FDA," said Daxor CEO and President, Michael Feldschuh. "Our team has made substantial strides in resolving critical issues, and this strategic shift allows us to capitalize on that progress. By focusing on the 510(k) pathway, we're streamlining our approach and potentially accelerating our time-to-market." The company's decision to transition to a simple 510(k) application is based on several factors: Significant progress in addressing key regulatory requirements Identification of a small set of additional technical data needed for approval Opportunity to expedite the approval process by focusing on 510(k) clearance Daxor plans to pursue a separate CLIA-waiver application subsequently, allowing for a mo
Show less
Read more
Impact Snapshot
Event Time:
DXR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DXR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DXR alerts
High impacting Daxor Corporation - Closed End Fund news events
Weekly update
A roundup of the hottest topics
DXR
News
- Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum [Yahoo! Finance]Yahoo! Finance
- Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales MomentumGlobeNewswire
- DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24GlobeNewswire
- Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual SummitGlobeNewswire
- Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic DeviceGlobeNewswire
DXR
Sec Filings
- 12/10/24 - Form 4
- 12/10/24 - Form 4
- 12/10/24 - Form 4
- DXR's page on the SEC website